Shares of Acadia (NAS: ACAD) are up 123% for November, for an incredible total of 363% for 2012. The company finally hit both its primary and secondary endpoints in its phase 3 trials of its first-in-class drug Pimavanserin, which treats Parkinson's disease psychosis, a condition in many as 50% of Parkinson's disease patients. The drug had previously failed to reach statistical significance because of the placebo effect in the control group, but it was able to adjust the trials to account for this and reach its goals. If these results can be repeated, then we can expect strong continued market bullishness for the company.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


The article November Boosted This Biotech Up 123% originally appeared on Fool.com.

David Williamson, Max Macaluso, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Socially Responsible Investing

Invest in companies with a conscience.

View Course »

Introduction to Preferred Shares

Learn the difference between preferred and common shares.

View Course »

Add a Comment

*0 / 3000 Character Maximum